Phosphate
Phosphate binder rule is disease-specific discrimination
In April, CMS issued guidance for the inclusion of oral-only drugs in the end-stage renal disease bundled payment. The directive included Xphozah as a renal dialysis service.
Orals in the payment bundle: What will the future hold?
Effective Jan. 1, 2025, CMS will begin including phosphate-binders in the end-stage renal disease prospective payment system bundle.
Ardelyx sues CMS about plan to place phosphate binders into ESRD payment bundle
Ardelyx Inc. is leading a lawsuit against CMS about plans by the agency to include oral-only phosphate-lowering therapies into the End-Stage Renal Disease Prospective Payment System by January 2025.
Legislation pushes for a delay in placing phosphate binders in the ESRD payment bundle
Congress is reviewing legislation that would delay inclusion of oral phosphate binders into the End-Stage Renal Disease Prospective Payment System bundled payment system.
CMS should keep oral phosphate-lowering therapies outside the dialysis payment bundle
As a nephrologist, it is my mission to promote equal health care access and to end racial disparities in the care of patients with kidney disease.
Combined tenapanor, sevelamer may control serum phosphate in certain patients on dialysis
PHILADELPHIA — Tenapanor in combination with sevelamer may control serum phosphate levels in patients with hyperphosphatemia on dialysis, according to data from ASN Kidney Week.
VIDEO: Unmet needs of patients with hyperphosphatemia
Healio spoke with Daniel Coyne, MD, professor of medicine in the nephrology division at Washington University School of Medicine, about the challenges of managing hyperphosphatemia, new treatments and therapies, unmet needs in hyperphosphatemia management and more.
VIDEO: Drugs in the pipeline for hyperphosphatemia management
Healio spoke with Daniel Coyne, MD, professor of medicine in the nephrology division at Washington University School of Medicine, about the challenges of managing hyperphosphatemia, new treatments and therapies, unmet needs in hyperphosphatemia management and more.
VIDEO: Biggest treatment challenges for patients with hyperphosphatemia
Healio spoke with Daniel Coyne, MD, professor of medicine in the nephrology division at Washington University School of Medicine, about the challenges of managing hyperphosphatemia, new treatments and therapies, unmet needs in hyperphosphatemia management and more.
VIDEO: Latest treatment advancements in hyperphosphatemia
Healio spoke with Daniel Coyne, MD, professor of medicine in the nephrology division at Washington University School of Medicine, about the challenges of managing hyperphosphatemia, new treatments and therapies, unmet needs in hyperphosphatemia management and more.